known under the brand names Copaxone and Glatopa, via a drug safety communication on 22 January. The products already have warnings of immediate post-injection reaction, chest pain, localised fat ...

Many reactions have happened within 1 hour of using Copaxone/Glatopa. Some signs and symptoms may be the same as those of an ...

Mylan’s long-awaited rival for Teva’s blockbuster multiple sclerosis drug Copaxone has been approved in the US, putting a large chunk of the Israeli firm’s revenues at risk. The timing could ...